Issuu on Google+

ESC Arabia

MOHAMMED R ARAFAH MBBS FACP FRCPC FACC PROFESSOR OF CARDIOLOGY


Agenda  The size of the problem .  Local Data Community based studies ACS Registry Medical Intervention Studies

 National Steering committee for

CV guidelines-Primary care .


The size of the problem - Heart disease causes 45% of early deaths in Middle East . - Middle East on "Edge of Epidemic" of heart disease .

The Global Health and the UAE: Asia-Middle East Connections Conference at the UAE University in Al Ain Jan 8, 2010


Coronary Artery Disease in Saudi Arabia Dr. M Al Nozha Mohammed Arafah et al SMJ 2004

Study objective was to determine the prevalence of CAD among Saudis of both sexes, between the ages of 30-70years. In rural as well as urban communities. 17232 persons were screened .


Coronary Artery Disease in Saudi Arabia

Dr. M Al Nozha Mohammed Arafah et al SMJ 2004

The prevalence of coronary artery disease within the Kingdom of Saudi Arabia stands at 5.5 percent of the population with higher prevalence among men and those living in urban areas


Coronary Artery Disease in Saudi Arabia

ď Źstatistically significant risk factors in KSA: age, male gender, body mass index (BMI), hypertension, current smoking, fasting blood glucose, fasting cholesterol and triglycerides


Prevalence of risk factors for CAD in KSA Risk Factor

Prevalence

Diabetes mellitus (FBG ≥7.0 mmol/l)

23.7%

Hypertension (BP ≥140/90)

26%

Current smoking

12.8%

Hypercholesterolemia (TC≥5.2 mmol/l)

53.9%

Hypertriglyceridemia (Trig ≥1.7 mmol/l)

39.9%

Obesity (BMI≥30)

35.6%


Metabolic syndrome in Saudi Arabia

Prevalence  

Males is 37.2% Females 42%

 Mansour Al- Nozha ,Akram Al- Khadra ,Mohammed R Arafah , et al 2005 Saudi Medical Journal 2005; Vol. 26 (12): 1918-1925


The Cardio-Metabolic Risk P<0.0001

P<0.0001 P<0.0001

6.7

5

4.6

4 3 2 1 0

Prevalence of DM

Prevalence of CAD

6

70 60

70

67.8

50 40 30 20

15.7

10 Yes

No

Metabolic Syndrome

0

Yes

No

Metabolic Syndrome

Prevalence of Hypertension

7

60

63.7

50 40 30 20

19.2

10 0

Yes

No

Metabolic Syndrome

Prevalence of: a) Coronary Artery Disease (CAD), b) Diabetes Mellitus (DM), c) Hypertension in subjects with metabolic Syndrome.


Diabetes, abdominal obesity and other risk factors prevalence among Saudi population Variables

Total (%)

(Metabolic Syndrome Health Survey)

Abdomin al obesitya (%)

High Triglyceride sb (%)

Low HDLc (%)

High Blood pressured (%)

High Fasting glucosee (%)

Gender Male

8253 (47.7)

25.2

47.6

74.8

42.2

40.7

Female

9040 (52.3)

55.2

33.7

81.8

33.5

35.4

30 - 39

5942 (34.4)

36.4

34.8

77.7

19.0

24.2

40 - 49

4901 (28.3)

46.5

41.6

79.9

36.1

38.1

50 – 59

3499 (20.2)

44.0

46.2

79.4

51.9

49.6

60 -70

2951 (17.1)

37.6

42.5

76.4

60.9

51.5

17293

6943

6778

13061

6488

6360

41

40.3

78.4

37.7

37.9

Age Group

Total of each component

a c e

% of study 100 sample Waist circumference: male >102cm; female > 88cm

HDL cholesterol in: male <1.03 mmol/L; female <1.29 mmol/L FPG ≥6.1 mmol/L

triglycerides ≥1.69 mmol/L d Blood pressure ≥130/ 85 mmHg b

Al-Nozha MM, Al-Khadra A, Arafah MR, et al. Saudi Med J 2005; Vol. 26 (12): 1918-1925.


Hypertensionâ&#x20AC;Ś

A growing burden Saudi Arabia High prevalence of hypertension in in KSA compared to other countries in Africa and Middle East

26 %

fer from f u s n o lati ia popu b a r A i of Saud

sion n e t r e hyp

1. Arnaout MS, Almahmeed W, Ibrahim M, et al. Current Medical Research & Opinion 2011; 27 (6): 1223â&#x20AC;&#x201C;1236.


Hypertension...

A disease that requires attention Control rate of hypertension was low

25%1

Cardiovascular disease was responsible for

47%

of all deaths in Saudi Arabia1

50% of Saudi diabetic patients failed to achieve their target BP of 130/85 mmHg1

1. Arnaout MS, Almahmeed W, Ibrahim M, et al. Current Medical Research Opinion 2011; 27 (6): 1223â&#x20AC;&#x201C;1236.


Prevalence, Awareness, Treatment, and Control of Hypertension among Saudi Adult Population: A National Survey Abdalla A. Saeed, * Nasser A. Al-Hamdan, Ahmed A. Bahnassy, Abdelshakour M. Abdalla, Mostafa A. F. Abbas, and Lamiaa Z. Abuzaid

Int J Hypertens. Published online 2011 September 6.


Result • Cross-sectional study. • Multistage stratified sampling was used to select 4758 adult participants. • The overall prevalence of hypertension was

25.5%.

• Only 44.7% of hypertensives were aware, 71.8% of them received pharmacotherapy, and only 37.0% were controlled.


RESULTS • Awareness was significantly associated with gender, age, geographical location, occupation, and comorbidity. • Applying drug treatment was significantly more among older patients, but control was significantly higher among younger patients and patients with higher level of physical activity. • Significant predictors of hypertension included male gender, urbanization, low education, low physical activity, obesity, diabetes, and hypercholesterolemia.


Conclusion Prevalence is high, but awareness, treatment, and control levels are low indicating a need to develop a national program for prevention, early detection, and control of hypertension


INTERHEART study

2 October 2012

ď&#x201A;&#x2014; The median age at presentation with myocardial

infarction was 51 years in the Middle East .

ď&#x201A;&#x2014; This was lower than the median age at

presentation in nine other regions, and was

12 years lower than the median age at

presentation in Western Europe .


Risk of acute myocardial infarction associated with risk factors in the overall Middle East population  Current smoking  Diabetes  Hypertension  Abdominal obesity  ApoB/ApoA1 ratio

55.81 23.36 22.90 56.37 43.47


Khalid AlHabib et al

Volume 23, Issue 4 , Pages 233-239, October 2011


Variables

STEMI/new NSTEACS Overall n=5055 LBBB n=2096 n=2959 (58.5%) P-value n (%) (41.5%) n (%) n (%)

Mean age (SD), 58 (12.9) years Male sex, n (%) 3914 (77.4) BMI, median 27.6 (6.1) (IQR) Diabetes 2937 (58.1) mellitus, n (%) Hypertension, n 2783 (55.3) (%) Current 1638 (32.4) smoking, n (%) Hyperlipidemia 2084 (41.4) , n (%)

55.4 (13.1)

58.6 (12.9)

<0.0001

1767 (84.3)

2147 (72.4)

<0.0001

27.4 (5.8)

28.1 (6.5)

<0.001

1092 (52.1)

1845 (62.3)

<0.0001

855 (40.9)

1928 (65.5)

<0.0001

903 (43.1)

734 (24.8)

<0.0001

559 (26.7)

1525 (51.9)

<0.0001


Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolemia


AHA 2011 announcement


Study Objectives To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according the 2004 updated NCEP ATP III


Study Objectives Primary Secondary

: overall and by country : in the following sub-

populations â&#x20AC;˘ primary/secondary prevention patients â&#x20AC;˘ patients with metabolic syndrome (NCEP III Definition)


Reason for prescribing lipid lowering drug(s) Overall (5457)

Primary Prevention

79.5%

Secondary prevention

27.27%

Familial hypercholesterolemia

1.19%


Result


Male

58.2%

Age (mean+SD) years

55.6 (11.3)

SBP (mean+SD) mmHg

132.0 (18.2)

DBP (mean+SD) mmHg

78.7 (10.3)

Body weight (mean+SD) kg

82.1 (17.4)

Waist circumference (mean+SD)

103.3 (13.9)

BMI (mean+SD)

31.4 (6.9)

History of CHD

30.7%

History of PAD

2.8%

History of Cerebrovascular Disease

3.6%


Current Smoker

11.9%

Diabetes

63.5%

Metabolic syndrome

37.1%

Arterial hypertension

66.6%

Family history of premature CVD

20.6%


Single LLD Statins

93.4%

Fibrates

0.9%

Other

0.5%

Combination LLD

5.2%


2004 Updated NCEP ATP III Risk profile


Proportion of patients attaining their 2004 updated National Cholesterol Educational Program Adult Treatment Panel III-recommended low-density lipoprotein cholesterol (LDL-C) goals, according to risk category

) goals, according to risk category


Attainment of low-density lipoprotein cholesterol (LDL-C) goals in the overall cohort, and in patients with primary and secondary prevention, metabolic syndrome (MS) and familial hypercholesterolemia (FH).


Positive predictors for achievement of LDL-C goals according to 2004-updated National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) and Third Joint European Task Force (TJETF) guidelines.


Patient- Physician Questionnaire Controversy between Physicians and patients

According to the Patient Questionnaire, Questionnaire, only 43.91% of patients had been informed about their cholesterol levels, even though, according to the Investigator Questionnaire, Questionnaire, physicians set individual target cholesterol levels for 70% of their patients.


% of Goal Achievement

Primary Prevention & Secondary prevention treatment


Overall patients goal Achievement


Conclusion â&#x20AC;˘ Although the risk of mortality for patients with coronary heart disease is well-known and a number of guidelines exist to reduce this risk,

hypercholesterolemia in the 6 Arabian Gulf countries surveyed is still being undertreated .


Steering Committee Members Health Care Professional

Institute

Dr.Mohamed Saeedi

MOH

Dr.farhan Al Shalaan

MOH

Pro.Mohamed Arafah

KKUH

Dr.Muayed AL Zaibag

KAMC

Dr.Khalid AL Nemer

SFH

Dr.Badr Al Mostafa

MOH

Dr.Mubasher Kharal

KAMC

Dr.Mohamed Al Yasaa

MOH


Cardio Metabolic Guidelines workshops Local Experts Workshop Workshop: :including including40 40experts expertsacross acrossthe thekingdom kingdomtoto analyze analyzethe thedata dataand andput puttheir theircomments comments

International Internationalexperts experts 1-1-Prof.Peter Prof.PeterJ.J.Lin LinMD MDCCFP CCFP Director of Primary Care Director of Primary CareInitiatives, Initiatives,Canadian CanadianHeart Heart Research ResearchCentre.-Canada Centre.-Canada 2-Prof. 2-Prof.P.J. P.J.Van Vander derWees Wees Dutch Harkness fellow Dutch Harkness fellowofofthe theCommonwealth CommonwealthFund Fund Harvard Medical School Harvard Medical School 180 180Longwood LongwoodAve Ave Boston, MA Boston, MA 3-Prof.Victor 3-Prof.VictorHuckell Huckell Prof.of cardiology Prof.of cardiology University UniversityofofBritish BritishColoumbia-Vancouver Coloumbia-VancouverCanada Canada


Where to start?


Conclusions  Cardiovascular Disease is the major cause of

mortality in our region (We are on the edge of an epidemic ) .  Cardiovascular Risk factors are very common and the prevalence is increasing .  Prevention will be the key theme at all health providers in the Kingdom of Saudi Arabia .  Both SHA and MOH made a grate efforts for prevention .


THANK YOU Prof. Mohammed Arafah


SHA24/035003